BIO triples in three days, is DeSci an old tree blooming anew?
- Core Thesis: Bio Protocol has upgraded its narrative from DeSci to an AI Agent-driven DeSci (Agentic DeSci), and launched the BioXP system and BioAgent Launchpad, constructing a positive flywheel of "staking – new issuance – governance." This propelled the BIO token to double in value within three days. However, the team's transfer of tokens to exchanges and the sector's reliance on narrative hype introduce uncertainty for the future.
- Key Elements:
- The BIO token price briefly broke through $0.066 on May 3rd, doubling in three days. It has since retreated to around $0.06, with a market cap currently reported at $127 million, far below its high of $1.1 billion at the start of the year.
- Narrative upgrade is key: shifting from Decentralized Science (DeSci) to AI Agent-driven DeSci, launching the BioXP system used for priority access to new token offerings and accumulating veBIO for governance voting.
- The ecosystem's new project, PeptAI, launched on May 1st, was oversubscribed 5.9 times within 30 minutes. As of May 4th, oversubscription reached 12.7 times ($633,000), with over 700 participants, creating a positive cycle: stake BIO → earn BioXP → participate in new offerings → engage in governance.
- The Bio Protocol ecosystem has raised over $50 million in funding and has approximately 90,000 community members. It previously completed a $6.9 million seed round led by Arthur Hayes' Maelstrom Fund.
- The team's multi-signature address transferred 120 million BIO tokens (worth approximately $5.031 million) to an exchange on May 3rd, sparking market concerns about a "pump and dump," though the price movement was minimal.
- The latest project, PEPTAI, has entered the wet lab phase, operating on a model of "AI Agent autonomous decision-making + on-chain information transparency," pushing DeSci towards the tangible business stage of a "replicable drug discovery pipeline."
- Short-term price action remains highly dependent on narrative hype, but the team's ambition targets the trillion-dollar healthcare market.
Original｜Odaily Planet Daily（@OdailyChina）
Author｜Wenser（@wenser 2010 ）
In the gradually warming crypto market, BIO, once hailed as the "Light of the DeSci Track," has also delivered an impressive report card: on May 3, its price briefly broke through $0.066, staging a doubling rally in just 3 days. Nearly a year and a half after the DeSci (Decentralized Science) craze at the end of 2024, Bio Protocol, which once bore the halo of a "Binance Launchpool project," has adapted to the AI era trend by championing the slogan "Agent Pays for Science." Whether this is an old tree blooming anew or a pump-and-dump scheme, the answer may soon become clear.
Bio Protocol's Old and New Narratives: From DeSci to Agentic DeSci
Examining the drivers behind BIO's price surge, in the author's view, the most crucial factor is its discovery of a new narrative aligned with the AI era—shifting from decentralized scientific research to AI Agent and agent-driven decentralized scientific research.
This is not only a further refinement of its market positioning but also a critical step to inject new vitality into the Bio Protocol ecosystem. Specifically, Bio Protocol's key actions are as follows:
- BioXP System: Built on the Bio Protocol V2 staking system, the BioXP system allows users to prioritize participation in Ignition Sales (new project fundraising), increase allocation quotas, and accumulate veBIO (governance voting power). This serves as the foundational framework for long-term ecosystem development.
- Funding Support: In September last year, Bio Protocol completed a $6.9 million seed round led by Arthur Hayes' Maelstrom Fund, with participation from Mechanism Capital, Animoca Brands, Presto Labs, and others, to advance its AI-driven Launchpad and BioAgents. It also previously received investment from Yzi Labs (formerly Binance Labs). Sufficient funding is a necessary guarantee for sustained development across market cycles.
- BioAgent Launchpad: Integrated with the BioAgents platform, this Launchpad focuses on the concept of "allowing anyone to deploy DeSci AI agents." The latestIgnition Sale project, PeptAI, launched on May 1 and was oversubscribed by 5.9 times within 30 minutes. As of May 4, it has been oversubscribed by 12.7 times ($633,000; token FDV calculated at $1 million, token price $0.1), with over 700 participants. The sale lasts 14 days, ending on May 14 at 9 PM. Regarding token allocation: 20% of the total PEPTAI supply will be airdropped to BIO stakers (veBIO holders, with a 6-month linear unlock); 5% is offered publicly through the Ignition Sale. Those without BioXP can also participate by minting or staking BIO directly. Thus, through the Ignition Sale mechanism, Bio Protocol has fostered a positive cycle of "staking BIO tokens → earning BioXP points → participating in project Ignition Sales → engaging in community governance."
According to official data, the total fundraising scale of the Bio ecosystem has exceeded $50 million, with a community of around 90,000 members.
Under this new flywheel effect, the BIO token continued its previous uptrend, surging from around $0.03 to $0.066 in just three days, and has now temporarily pulled back to around $0.06.
Of course, while narrative updates and project iterations are one aspect, the Bio Protocol team's active market-making or potential distribution of tokens is another key focus for the market.
Pump-and-Dump or Active Market-Making? A Look at the Ambition of the Bio Protocol Team
On the morning of May 3, according to monitoring by crypto analyst Ai Yi @ai_9684xtpa , BIO rose 118% over the past week. That day, the multisig address of the Bio Protocol project team transferred 120 million BIO to 3 addresses, of which approximately 80 million were moved to OKX and Binance, valued at about $5.031 million.
On the other hand, Binance officially announced that it would add trading pairs like BIO/USDT to its isolated margin platform starting April 28, 2026, at 16:00 (UTC+8), adding fuel to BIO's rally from the margin and futures side.
For now, BIO's market cap stands at approximately $127 million, still significantly behind its peak of $1.1 billion in early 2025. Furthermore, the Bio Protocol team's recent operation did not cause major volatility in BIO's price. Combined with the broader crypto market recovery to over $80,000, BIO's price may continue its upward trajectory.
More importantly, research for PeptAI, Bio Protocol's latest Ignition Sale project, has entered the wet lab experimentation phase. Operating under an "AI Agent autonomous decision-making + on-chain information transparency" model, it is, to a certain extent, pushing the DeSci track—previously focused more on proof-of-concept—into the real business stage of "a replicable drug discovery production line."
From this perspective, the ambition of the Bio Protocol team has always been significant. After all, they are targeting the trillion-dollar healthcare market.
Of course, considering the niche nature and regulatory barriers of the DeSci track, in the short term, BIO's price trajectory for the rest of the year remains highly dependent on concept speculation.
Recommended Reading:
The Light of DeSci? A Guide to Binance Launchpool's Latest Project BIO
